Fig. 2

ABBV-176 efficacy against human tumor xenograft models in vivo. The in vivo tumor growth inhibition is shown for tumors in mice dosed as indicated by the arrows with the specific therapeutic or IgG matched non-targeted controls ((−)Co ADCs) as indicated in the legends of each panel. Tumor volumes are shown as mean ± S.E.M. (A) Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.5 mg/kg, h16f-MMAE ADC at 3 mg/kg, or matching controls (groups of n = 10). (B) BR-0869 TNB PDX tumor-bearing mice were dosed Q7D × 3 with ABBV-176 between 0.3 mg/kg and 0.01 mg/kg or 3.0 mg/kg of h16f-MMAE ADC (groups of n = 10). (C) Mice implanted with breast PDX tumor CTG-0670 were dosed with ABBV-176 or control PBD ADC at 0.2 mg/kg or 0.1 mg/kg, and h16f-MMAE at 3 mg/kg, all at Q7D × 3 (groups of n = 8). PRLR expression levels for 8 of the PDX models tested are shown in (D) and those expression values are shown relative to the TCGA breast cancer data for PRLR in (E). (F) Survival curves are shown for mice implanted with the HepG2 HCC model (groups of n = 10), where mice were dosed Q7D × 3 with vehicle, 0.2 mg/kg control PBD, or 0.2 mg/kg ABBV-176